Chemo: The Cash Cow of the Cancer Industry

Cash Cow, defined
From Wikipedia, the free encyclopedia (1/10/10)

"In business, a cash cow is a product or a business unit that generates unusually high profit margins: so high that it is responsible for a large amount of a company's operating profit. This profit far exceeds the amount necessary to maintain the cash cow business.

A firm is said to be acting as a cash cow...when the firm is not investing in product improvements and is essentially considering itself not in a growth market. This could be the case if a company sees the future of a product line as bleak as a result of some other technology taking away its market share.

Risks of a cash cow include complacency, with management ignoring the need for change as market forces erode value.

That said, every business longs for a cash cow product. The BCG growth-share matrix developed by the Boston Consulting Group, still used by analysts in large companies, uses the term "cash cow" to describe business units experiencing high market share and low market growth.

["Cash cow"] is a business metaphor rooted in the notion of a dairy cow that can be milked on an ongoing basis..."

Chemo is the Cash Cow of the Cancer Industry. However, as the Cancer Industry controls and monopolizes the market through cooperation of complicit regulatory and research agencies, there is no market force present to erode value. Obscene profits continue to roll in on the backs of deceived cancer patients. The Cancer Industry is insulated from the normal forces of the market place, which, if allowed to exist, would force it to 1) recall all chemotherapy products as unsafe; and 2) introduce safer products into the marketplace.


Just say no to chemo.